Short-acting DMT is the most counterintuitive object in the current psychedelic research pipeline. The acute experience runs for roughly 20 to 30 minutes when vaporized, and the plasma half-life sits at approximately 9 minutes according to the pharmacokinetic literature, which is more than 15 times shorter than the 3-hour half-life of psilocin. Across the integration sessions I have run with participants who completed registered DMT trials or ayahuasca retreats, the pattern is consistent. The brevity of the acute window does not predict the size of the integration load that follows it.
This article works through what the phase 2 trial data actually shows, why short-acting DMT is producing antidepressant signals that compare favorably to psilocybin, and why the integration protocol still matters even when the dosing event itself fits inside a half-hour clinical window. The anchor publications are the Erritzøe and colleagues 2025 phase 2a randomized controlled trial in Neuropsychopharmacology, the Luan and colleagues 2024 work on extended DMT effects in the Journal of Psychopharmacology, and the Cybin SPL026 phase 2a program data. For the broader integration arc that any psychedelic session connects to, see the afterglow window and what happens in an integration session.
The framing for everything that follows is plain. DMT therapy is not ayahuasca compressed. It is a different pharmacological object with its own integration demands, its own neuroscience, and its own emerging clinical evidence base.
- Erritzøe and colleagues 2025 reported a 10.8-point greater MADRS reduction at one week against placebo in vaporized DMT for treatment-resistant depression, with roughly 77 percent of active-arm participants meeting response criteria by day 7.
- DMT plasma half-life is approximately 9 minutes, compared to roughly 3 hours for psilocin, making it the shortest-acting clinically studied classic psychedelic.
- The Cybin SPL026 phase 2a trial used intravenous DMT at 21.5 mg in 34 participants, producing antidepressant signals that align with the vaporized DMT trial direction.
- Acute duration does not predict integration load. The Luan 2024 work showed neural and subjective effects extending well past the 30-minute acute window.
- DMT therapy and ayahuasca diverge on pharmacokinetics, content character, and integration arc, which means ayahuasca integration models do not transfer directly.
What Is DMT Therapy, and How Is It Delivered?
DMT therapy in current trials uses pure N,N-dimethyltryptamine delivered intravenously or as a vaporized inhalation, producing an acute experience of roughly 20 to 30 minutes with a plasma half-life of about 9 minutes. The Erritzøe and colleagues 2025 phase 2a study used vaporized SPL026 in treatment-resistant depression participants, while parallel Cybin programs have used intravenous dosing protocols. The delivery route shapes the rise curve more than the peak intensity.
This is the central pharmacokinetic point. Oral DMT is destroyed in the gut by monoamine oxidase and produces no effect on its own. Ayahuasca works by combining DMT with a monoamine oxidase inhibitor that protects it from gut breakdown, which is why the oral preparation produces a 4 to 6 hour journey. Intravenous and vaporized routes bypass that breakdown entirely. The result is a fast, intense, and short acute experience that fits inside a clinical session of under an hour.
Vaporized vs Intravenous Delivery
Vaporized DMT, used in the Erritzøe phase 2a, produces a rise to peak within roughly two minutes and a return to baseline by about 20 to 30 minutes after administration. Intravenous DMT, used in early Strassman-era work at the University of New Mexico and in current Cybin SPL026 dosing, can be delivered as a bolus or as a continuous infusion. Infusion protocols allow the experience to be extended and titrated, which addresses one of the central integration challenges of the brief breakthrough format.
What the Acute Experience Looks Like
The vaporized DMT experience typically opens with a rapid perceptual cascade. Geometric visual content, ego dissolution, and what participants frequently describe as encounters with apparently autonomous presences are common features. Roland Griffiths and colleagues, before Griffiths' death, had characterized similar content as falling within the same phenomenological family as the high-dose psilocybin mystical experience, though the rapid onset compresses the arc.
Erritzøe and colleagues published their phase 2a randomized controlled trial in Neuropsychopharmacology in 2025, testing vaporized SPL026 dimethyltryptamine in patients with treatment-resistant depression. The trial reported a 10.8-point greater reduction on the Montgomery-Åsberg Depression Rating Scale at one week compared to placebo, with approximately 77 percent of active-arm participants meeting standard response criteria by day 7. The clinical implication is that short-acting DMT can produce antidepressant effects comparable in magnitude to those previously reported for psilocybin in similar treatment-resistant populations. The sample size and one to twelve week follow-up windows leave the durability question open, but the direction and magnitude of the signal are clearly within the range that supports continued phase 3 investment.
What Does the Phase 2 Trial Data Actually Show?
The Erritzøe 2025 phase 2a randomized controlled trial reported a 10.8-point greater MADRS reduction at one week compared to placebo, with roughly 77 percent of active-arm participants meeting response criteria by day 7 (Erritzøe et al., 2025). For reference, the Carhart-Harris and colleagues 2021 NEJM trial on psilocybin versus escitalopram and the COMPASS Pathways psilocybin phase 2b reported MADRS reductions in a similar range. The magnitudes are in the same range, which is a meaningful early signal for a substance with a 30-minute acute window. Subsequent network analyses by Daws and colleagues in Nature Medicine 2022 have helped characterize the neural correlates of antidepressant response.
The Cybin SPL026 Program
Cybin's SPL026 phase 2a, which used intravenous DMT at a 21.5 mg dose in 34 participants with major depressive disorder, produced antidepressant signals that align with the vaporized DMT direction. The dosing approach combines an initial bolus with structured therapy support before and after the experience. The follow-up windows reported in interim data extend across multiple weeks, though the full peer-reviewed publication trail is still emerging as of mid-2026.
Extended Effects Beyond the Acute Window
Luan and colleagues published in 2024 in the Journal of Psychopharmacology a characterization of extended DMT effects past the acute window (Luan et al., 2024). The work documented persistent changes in subjective wellbeing, mood, and functional brain connectivity measurable for days after a single dosing session. This is the same plasticity window pattern observed with psilocybin, with the practical implication that the integration opportunity opens at the moment the participant returns to baseline consciousness, not later.
How DMT Compares to Psilocybin Outcomes
The early signal is that short-acting DMT can produce antidepressant effects in the same range as psilocybin for treatment-resistant depression, with a much shorter clinical session footprint. The implication for healthcare delivery is potentially significant. A 30 to 60 minute clinical visit fits inside existing infusion clinic infrastructure in a way that a 6-hour psilocybin session does not. The cost-per-treatment trajectory differs, and that economic logic is one of the reasons phase 3 investment is following.
How Is DMT Therapy Different from Ayahuasca?
DMT therapy and ayahuasca share a primary active compound and almost nothing else, with DMT's roughly 9-minute half-life standing against ayahuasca's 4 to 6 hour journey driven by the monoamine oxidase inhibition of banisteriopsis caapi. The pharmacokinetic divergence creates downstream divergence in subjective character, integration arc, and clinical risk profile. Ayahuasca integration heuristics do not transfer one-to-one to DMT therapy.
The MAO inhibition piece of ayahuasca matters beyond just protecting DMT from gut breakdown. It exposes the participant to several hours of altered monoamine metabolism, which is what underlies the well-documented dietary and pharmaceutical interaction risks of ayahuasca, including tyramine, SSRIs, and a range of stimulants. DMT therapy administered intravenously or by vaporization carries none of that MAO inhibition load, which substantially reduces the interaction risk profile while leaving most of the 5-HT2A receptor agonism intact.
Subjective Content Differs
The phenomenology of vaporized or intravenous DMT tends toward rapid breakthrough content, abstract perceptual phenomena, and what participants often describe as encounters with apparently autonomous entities. Ayahuasca more often produces autobiographical, narrative, somatic, and family-system content unfolding across hours. Both can produce mystical-type experiences scored on the MEQ30. The texture of what shows up differs in ways that change what integration work the participant then needs to do.
Integration Arc Compresses, It Does Not Disappear
A 4 to 6 hour ayahuasca journey provides built-in processing time during the experience itself. Material surfaces, gets examined, gets re-examined, and partly integrates within the same dosing window. A 25-minute DMT breakthrough does not. The same volume of material can surface, but the integration work happens almost entirely after the acute window closes. The implication for integration coaching is that DMT participants often need denser post-session support than ayahuasca participants, not less.
Risk Profiles Are Not Equivalent
The MAO inhibition window of ayahuasca creates a specific medication and dietary interaction profile that DMT therapy does not share. DMT therapy still carries the standard classic psychedelic contraindications, including bipolar spectrum, primary psychotic disorders, and cardiovascular caution. The risk profiles overlap on the 5-HT2A side and diverge on the MAO side. Comparing the two as if they were the same substance produces miscalibrated decisions in both directions.
The Luan and colleagues 2024 publication in the Journal of Psychopharmacology characterized extended subjective and neural effects of DMT past the acute dosing window, including persistent functional connectivity changes measurable in the days following a single administration. Strassman's commentary in Nature Medicine in 2025 framed the renewed clinical interest in short-acting DMT as both an extension of his University of New Mexico work in the 1990s and as a substantively new clinical object given the addition of structured therapy support, modern dose-response data, and randomized controlled trial designs. The clinical implication is that the plasticity window opens at the moment the participant returns to baseline consciousness rather than at the end of a several-hour pharmacological exposure, which moves the integration emphasis earlier in the post-session arc.
Why Do Brief DMT Sessions Still Need Full Integration?
The central paradox of DMT therapy is that the briefest acute experience among classic psychedelics often produces the densest integration load, because the post-session plasticity window opens earlier and the participant arrives at it carrying compressed novel content. The Luan 2024 work shows neural and subjective effects extending well past the 30-minute pharmacological window, which means the integration opportunity is real and time-bound. Brevity at the front end concentrates rather than dilutes the work at the back end.
This pattern shows up consistently in the integration sessions I run with participants who have completed registered DMT trials or comparable structured experiences. The expectation walking in is often that a short experience will need short integration. The experienced reality is the opposite. A 25-minute breakthrough that produces an ego dissolution event or a perceived encounter with apparently autonomous content frequently generates more material per minute than a longer-arc session does.
The Plasticity Window Opens at Re-entry
Post-session neuroplasticity, mediated by BDNF expression, glutamate signaling shifts, and 5-HT2A-driven dendritic spine formation, is what makes any psychedelic session a therapeutic intervention rather than a one-off experience. For an overview of the glutamate piece, see glutamate and psychedelics. With DMT, that plasticity window opens within minutes of the acute experience ending. The first 48 to 72 hours after re-entry are particularly active.
Content Compression Increases, Not Decreases, Load
Compression matters because the integrative work depends on what is metabolized, not on how long the participant spent in the acute state. A short ego dissolution event followed by a perceived encounter with entity content can produce as much material to integrate as a 6-hour ayahuasca journey through a chronological autobiographical arc. The mistake is treating acute duration as the proxy for integration depth.
Decision-Making in the Afterglow
The post-session window is also when participants are most likely to make significant life decisions, including ending relationships, changing careers, or restructuring businesses. The acute brevity of DMT does not change this, and in some ways amplifies it because the participant feels they have "recovered" and is back to baseline before the plasticity window has really closed. For more on this specific risk, see psychedelics and decision-making.
"The participants I work with after a registered DMT trial often arrive at the second integration session expecting they are done. They are not done. The acute experience took 25 minutes. The integration arc takes four to six weeks if it is going to take less than that. The pharmacokinetics and the integration timeline are not the same variable."
What Does an Integration Protocol for DMT Therapy Look Like?
A working integration protocol for short-acting DMT typically includes one pre-session preparation conversation, immediate post-session debrief within 24 hours, and two to four structured integration sessions across the four weeks following dosing. The denser front-end timing reflects the compressed acute window and the early opening of the plasticity arc. Aaronson and colleagues' broader psychedelic-assisted therapy work supports the structure as a generalizable model.
Pre-Session Preparation
Preparation for a DMT session covers intention setting, screening review, expectation calibration, and what to do during a difficult experience. Because the acute window is so short, there is little opportunity to course-correct in-session. Preparation has to do work that ayahuasca preparation can defer to the journey itself. Specific topics to cover include orienting the participant to the rapid onset, normalizing the experience of being unable to verbalize during peak intensity, and rehearsing a return-to-body protocol for the post-acute window.
Day-of and First 24 Hours
The first 24 hours after a DMT session is when the early plasticity window is most active and when participants are most likely to begin assembling a narrative interpretation of the experience. A short debrief within hours of the session, often a 20 to 30 minute structured conversation, helps prevent premature narrative closure. The goal is not interpretation. The goal is to keep the material open and accessible for the work that comes next.
Weeks One Through Four
The post-session integration arc benefits from two to four structured sessions distributed across the four weeks following dosing, with the first session typically within 72 hours. The MEQ30 mystical experience score during the session is often the strongest predictor of long-term outcomes, and for more on that mechanism see the MEQ30 as predictor. Integration sessions in this window focus on translating experiential content into specific behavioral or relational shifts, rather than on interpretation alone.
Beyond Week Four
By week four to six, the acute plasticity window has typically closed and the integration emphasis shifts toward sustaining the changes initiated in the first month. This is where retreat and trial participants most often disengage, and where the actual durability of the antidepressant or psychological gain is determined. The Erritzøe phase 2a follow-up windows of one to twelve weeks fall inside this arc, which is part of why durability remains an open question in the published data.
Is DMT Therapy Legally Available Today?
DMT remains a Schedule I controlled substance in the United States and is similarly classified under the United Nations 1971 Convention on Psychotropic Substances internationally, with legal access today restricted to enrollment in registered clinical trials. Cybin, Small Pharma (now part of Cybin), and other developers are running phase 2 and planned phase 3 trials. Religious exemptions exist for certain ayahuasca contexts but do not extend to pure DMT therapy.
For prospective participants, the practical map of legal access today is clinical trial enrollment, primarily through Cybin's ongoing programs in the United States, the United Kingdom, and select other jurisdictions. The eligibility criteria typically require a confirmed diagnosis of treatment-resistant depression or major depressive disorder, failure of at least two prior antidepressant trials, and screening against the standard psychedelic contraindication list including bipolar spectrum and primary psychotic disorders.
What Phase 3 Approval Would Change
If the phase 2 signal holds through phase 3, regulatory submission to the FDA and the EMA becomes plausible in the late 2020s or early 2030s. The COMPASS Pathways psilocybin phase 3 trajectory provides a partial reference for the timeline. Approval would shift DMT therapy from research-only access to a Schedule III or comparable medical-use category, opening the door to clinic-based delivery within existing infusion infrastructure.
Integration Coaching in the Current Window
For people who have completed a registered DMT trial or who are processing a comparable experience from another setting, integration coaching is a legal post-experience support modality focused on meaning-making, behavioral integration, and afterglow window utilization. It is not therapy, not medical care, and not a substitute for either. The framing matters because the substance pharmacology may be Schedule I while the post-experience coaching is firmly within legal scope.